Compare BioNTech SE - ADR (BNTX) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Intuitive Surgical, Inc. — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Intuitive Surgical, Inc. trades at $382.15 (market cap $134.40B). The key difference: Intuitive Surgical, Inc. is far larger — about 5.9× BioNTech SE - ADR's market cap, and BioNTech SE - ADR is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| BNTX | ISRG | |
|---|---|---|
Market Cap | $22.86B | $134.40B |
Sector | Health | Health |
52-Week High | $119.34 | $592.85 |
52-Week Low | $83.89 | $379.50 |
Enterprise Value | $6.53B | $129.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Intuitive Surgical (ISRG) trades at $407.12, showing minimal daily change. The stock is in a bearish technical trend but maintains strong fundamentals with consistent revenue growth, expanding profit margins, and a history of earnings beats. Recent news highlights near-term headwinds and a significant decline from 52-week highs, yet analyst sentiment remains largely positive, focusing on long-term robotic surgery market penetration.
The outlook balances strong fundamentals against technical weakness. Investment opportunity lies in market leadership and earnings growth potential, but risks include competitive pressures and execution challenges. Wall Street consensus is bullish with a $557.60 price target, suggesting substantial upside if the company navigates current challenges successfully.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
